How did Lipocine's revenue surge in Q1 2024?

Lipocine's revenue surge in Q1 2024 can be attributed to **LPCN 1148**.

1. **LPCN 1148's Positive Results**: Lipocine reported positive topline results from a Phase 2 clinical study of LPCN 1148 in patients with cirrhosis, meeting primary and Hepatic Encephalopathy endpoints. These results demonstrate the drug's potential for treating patients with cirrhosis, a significant unmet medical need.
2. **Market Opportunity**: The market size for cirrhosis treatment is substantial, with a strong pharmaco-economic rationale for a novel therapy like LPCN 1148. This opens up a significant market opportunity for Lipocine.
3. **Development Path**: Lipocine plans to meet with the FDA to discuss a development path to NDA filing, indicating a potential near-term revenue impact from LPCN 1148.

In conclusion, Lipocine's revenue surge in Q1 2024 is primarily driven by the positive results from the Phase 2 clinical study of LPCN 1148, which has opened up a significant market opportunity for the company.